T
6.58
0.63 (10.59%)
| Penutupan Terdahulu | 5.95 |
| Buka | 6.20 |
| Jumlah Dagangan | 9,023,214 |
| Purata Dagangan (3B) | 2,630,639 |
| Modal Pasaran | 669,482,112 |
| Harga / Buku (P/B) | 5.68 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2025 - 11 Aug 2025 |
| EPS Cair (TTM) | -0.450 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.96% |
| Nisbah Semasa (MRQ) | 15.38 |
| Aliran Tunai Operasi (OCF TTM) | -41.27 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -24.53 M |
| Pulangan Atas Aset (ROA TTM) | -34.41% |
| Pulangan Atas Ekuiti (ROE TTM) | -55.12% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Trevi Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
2.0
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.5 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | -0.5 |
| Purata | 2.00 |
|
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.75% |
| % Dimiliki oleh Institusi | 75.65% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 25.00 (Cantor Fitzgerald, 279.94%) | Beli |
| Median | 22.50 (241.95%) | |
| Rendah | 21.00 (HC Wainwright & Co., 219.15%) | Beli |
| 21.00 (D. Boral Capital, 219.15%) | Beli | |
| Purata | 22.75 (245.75%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 6.17 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Cantor Fitzgerald | 01 Jul 2025 | 25.00 (279.94%) | Beli | 5.62 |
| D. Boral Capital | 02 Jun 2025 | 21.00 (219.15%) | Beli | 6.32 |
| HC Wainwright & Co. | 28 May 2025 | 21.00 (219.15%) | Beli | 6.26 |
| Needham | 20 May 2025 | 24.00 (264.74%) | Beli | 6.47 |
| 08 Apr 2025 | 24.00 (264.74%) | Beli | 5.30 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |